INTRODUCTION
Low levels of high-density lipoprotein cholesterol (HDL-C) are an independent risk factor for the development of cardiovascular disease (CVD). The ATP-binding cassette transporter A1 (ABCA1) facilitates the rate-limiting step in HDL formation, the efflux of cellular lipid onto apolipoprotein A-I (apoA-I). Over 150 unique ABCA1 mutations have been reported (see http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ABCA1) and impaired ABCA1 activity associated with mutations in ABCA1 is a major genetic cause of low HDL-C levels (1, 2) . The reduced function of many of these has been attributed to intracellular retention and prolonged residence in the endoplasmic reticulum (ER), leading to mislocalisation to the plasma membrane (1, 3, 4) . Mutations that cause misfolding are an 4-PBA is a short chain fatty acid that can rescue the detrimental phenotype of misfolded, mislocalised proteins in vitro and in vivo (6) . In particular, 4-PBA can restore functionality to mutant ATP binding cassette transporters including ABCA3, ABCD2, ABCC6, ATPB7 and CFTR (7) (8) (9) (10) (11) , which prompted its use here. 4 -PBA has been used in a wide range of clinical applications including routine treatment of patients with cystic fibrosis, thalassemias, urea cycle disorders and cancer (6) . Treatment of CFTR mutants responsible for cystic fibrosis has shown that 4-PBA ameliorates ER retention and is sufficient to restore protein function in vitro and in vivo (11, 12) . Mechanisms for its action include the ability to act as a chaperone (13) , reduce ER stress (14) , transcriptionally upregulate chaperone proteins (15) , provide histone deactylase inhibitor activity (16) and scavenge ammonia (17) . The application of chemical chaperones to ABCA1 has not been described, however, mutant ABCA1 proteins with aberrant cellular localisation are suitable candidates for such treatment. We investigated the impact of 4-PBA on nine naturally occurring ABCA1 missense mutants. Six of the ABCA1 mutations were previously identified in low HDL-C subjects and included three uncharacterised mutations, p.I659V, p.R2004K and p.A2028V (18) and three variants, p.R1068H, p.T1512M and p.N1800H, known to have reduced localisation and cholesterol efflux (19, 20) . We identified a further three novel mutations, p.A594T, p.Y1767D and p.Q2239N, and these were also included in this study. We hypothesised that efflux function would be improved for mutants that are dysfunctional as a result of protein mislocation. The results presented here provide the first evidence that chaperone-mediated restoration of mutant ABCA1 cellular localisation improves efflux function. 
MATERIALS AND METHODS

ABCA1 gene analysis
The study was approved by the Lower South Regional Ethics Committee. All subjects gave informed consent and all procedures were in accordance with institutional guidelines. Screening of the ABCA1 gene in ten low HDL-C subjects (<0.8 mmol/L) was performed by PCR amplification and sequencing of all 50 exons of the ABCA1 gene (20) .
Primer sequences are provided in Supplementary Table 1. All PCR reactions contained 10 ng DNA, 14 pmol each of the forward and reverse primers, 1x Roche Faststart Taq PCR buffer (2 mM MgCl2), 200 µM each dNTP, 1 U Faststart Taq DNA polymerase (Roche; Mannheim, Germany) and MilliQ water to a final reaction volume of 20 µL. A two-step PCR amplification program was used and consisted of an initial denaturation step of 5 minutes at 95°C followed by 10 amplification cycles of denaturation at 95°C for 48 seconds, annealing at 63°C for 48 seconds followed by extension at 72°C for 48 seconds. These cycles were repeated a further 25 times with the annealing temperature dropped to 61°C. A final extension, of 10 minutes at 72°C, was performed and the reactions were held at 4°C. A decreased annealing temperature combination of 59 to 57°C was used to amplify exons 17 and 44. Annealing at 61 to 59°C was used for exons 38 and 39, and 66 to 64°C for exons 10, ! 6! contained; 1x Pfu Buffer, 200 !M dNTPs, 0.5 !mol each of the forward and reverse mutagenic primers, 75 ng template plasmid DNA, 0.4 U Pfu polymerase and MilliQ water to make up a 20 !L reaction volume. Cycling parameters consisted of initial denaturation at 98°C for two minutes followed by 35 cycles of denaturation at 98°C for forty seconds, annealing at 55°C for one minute and extension at 72°C for fifteen seconds per kb of template DNA. A final extension at 72°C for 10 minutes was performed. The mutation position and the entire cDNA insert for all vectors were verified by sequencing.
Cell culture
Primary fibroblast cultures were established from 2 mm punch biopsies (20) and were cultured in Advanced Dulbecco's Modified Eagle Medium (DMEM). Human embryonic kidney 293 (HEK293) cells were obtained from the American Type Tissue Collection (Manassas, VA) and maintained in DMEM. Both media were supplemented with 10% foetal bovine serum (Bio International; Auckland, New Zealand), 2 mM L-glutamine, 0.25 µg/mL amphotericin B, 100 U/ mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified environment with 5% CO 2 . Unless otherwise stated, all cell culture reagents were purchased from Invitrogen (Carlsbad, CA). A 100 mM stock of 4-PBA (Tocris Bioscience; Ellisville, MO) was made using sterile water and diluted to a 10 mM working stock in serum-free culture medium. Culture medium was replaced with 4-PBA supplemented serum-free medium for twenty-four hours prior to the experiment endpoint. ApoA-I protein used for functional experiments was isolated from normolipidemic human plasma according to the method of Brace et al., (21) and was presented to cells in serum-free medium supplemented with 10 mM 4-PBA when appropriate. 
Cholesterol efflux assays
Cholesterol efflux assays were performed using primary fibroblast cells and transfected HEK293 cells as described previously (20) . Twenty four hours after cells were seeded, the culture medium was replaced with fresh medium containing 0.5 µCi/well total radioactivity present in the medium fraction. Non-specific efflux, in the absence of apoA-I, was determined and subtracted from each experimental measurement.
Confocal microscopy
The cellular localisation of ABCA1-GFP proteins was examined using confocal microscopy (19) . Transfected HEK293 cells were cultured on poly-L-ornithine coated glass coverslips and 48 hours following transfection the cells were incubated in serum-free medium overnight. The following day, cells were incubated with fresh medium containing 10 µg/mL apoA-I for 6 hours. Cells were fixed using 4% formaldehyde and stained with 5 µg/mL AlexaFluor594 Wheat Germ agglutinin (Invitrogen) to label cell membranes and mounted on glass slides. Images were obtained using a Zeiss LSM 510 confocal microscope with the Argon (488 nm) and HeNe (633 nm) lasers and were analysed using the Zeiss LSM Image Examiner software. The Pearson's correlation coefficient between the GFP and AlexaFluor594 signal was calculated from images using the Colocalisation Finder plugin of the ImageJ software.
Protein isolation and western blot analysis
Western blots of cell lysates were performed as described previously (19) . Cells were grown to confluence and lysed in RIPA buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)) supplemented with complete mini protease inhibitors (Roche). Lysates were separated by SDS-PAGE using 7.5% gels and transferred to nitrocellulose membrane. Membranes were 
RNA isolation and quantitative RT-PCR
Total RNA was isolated from cells cultured to confluence using the RNeasy mini kit ABCA1 mRNA expression relative to GAPDH was calculated from in-run standard curves.
Luciferase reporter gene assays
The transcriptional response of the native ABCA1 promoter to 4-PBA was examined using HEK293 cells transfected with luciferase reporter constructs. To create an ABCA1
promoter reporter vector, a 715 bp region (position -714 to +1) of the wildtype ABCA1
promoter was amplified and cloned into the pCR2.1 entry vector (Invitrogen). A 700 bp region of the promoter (position -699 to +1) was then subcloned from the pCR2. Table 4) . Cells were transiently co-transfected with 0.5 µg of the ABCA1-promoter pGL4.10 vector, and 5 ng of the phRL-SV40 vector, designed to constitutively expression renilla luciferase. Growth medium was replaced 24 hours following transfection with fresh medium, containing 4-PBA when required. After a further 24 hours, cell lysates were harvested and assayed for renilla and firefly luciferase activity using the Dual Luciferase® Reporter Assay System (Promega). Firefly luciferase measurements were normalised to renilla measurements and expressed relative to untreated ABCA1 promoter activity as 1.0.
Data analysis
Data are expressed as mean + SEM unless otherwise stated. Differences of means were assessed using the Student's t-test or one-way ANOVA with Bonferroni post-hoc comparisons.
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RESULTS
ABCA1 mutants with impaired localisation have reduced cholesterol efflux function
We identified three novel ABCA1 variants, p.A594T, p.Y1767D and p.Q2239N, in heterozygote form in three individuals with HDL-C levels of 0.61, 0.17 and 0.37 mmol/L respectively. The individual heterozygote for p.Y1767D was also heterozygote for the p.N1800H ABCA1 mutation. The position of all ABCA1 protein variants investigated within this study is shown in Fig. 1 .
We first characterised the three novel ABCA1 mutants and three previously blotting using an anti-GFP antibody (Fig. 2C) . Quantification of the western blot images showed the ABCA1-GFP signal to be comparable across all genotypes (as assessed using However, the cholesterol efflux of the p.R1068H mutant was unable to be restored to wildtype levels. Interestingly, the cholesterol efflux of the wildtype ABCA1-GFP transfected cells was also significantly increased after 4-PBA treatment (Fig. 3B) . Treatment of transfected HEK293 cells with 4-PBA increased ABCA1-GFP protein level by a similar fold increase (1.4 to 1.8 fold) across all genotypes including wildtype ( Fig. 3C and D) .
Furthermore, 4-PBA increased the level of wildtype and mutant ABCA1-GFP mRNA (1.8
fold to 2.1 fold) in transfected cells (Fig. 4) . These results indicate that 4-PBA promotes a similar transcriptional upregulation of the heterologous promoter within the wildtype and mutant ABCA1-GFP vectors that results in an increased ABCA1 protein level.
4-PBA improves mutant ABCA1 efflux function independent of protein level in primary fibroblasts
We assessed the effect of 4-PBA treatment in the context of the native ABCA1
promoter, using available p.R1068H, p.N1800H and wildtype primary fibroblast cell lines (19, 20) . Fibroblasts were obtained from two p.R1068H heterozygote carriers (RH1 and RH2), two p.N1800H heterozygote carriers (NH1 and NH2) and from two ABCA1 wildtype subjects (WT1 and WT2). The mutant carriers RH1, RH2 and NH1 were confirmed to carry no other ABCA1 mutations on either their mutant or wiltdype alleles. We had previously determined that subject NH2 was also heterozygous for the p.C978fsX988 mutation, which encodes a truncated protein that is functionally null and in this individual was present on a seperate allele to the p.N1800H mutation (20) .
The cholesterol efflux function of the mutant fibroblast cell lines was lower than the efflux from wildtype cells (Fig. 5A) , as previously shown (19, 20 In contrast to transfected HEK293 cells, the ABCA1 protein level was decreased for all wildtype and mutant fibroblast cell lines following 4-PBA treatment (Fig. 5B ). There was a similar decrease in protein level for most cells lines with a greater decrease for RH2 cells (p<0.05), as assessed using one-way ANOVA (Fig. 5C ). Further investigation, using luciferase reporter assays, showed 4-PBA to decrease the transcriptional activity of the native ABCA1 promoter (Fig. 6) Improved positioning of ABCA1 at the plasma membrane has been shown previously for a p.Q597R mutant under conditions of induced ER stress, however, in that instance no improvement in efflux activity was seen (23) . This is in contrast with our results where the majority of the mutants showed significant improvements in function, including the p.A594T mutant, which is of a similar location to p.Q597R. This discrepancy could be due to the mechanism by which plasma membrane localisation was restored by the two different treatments. Plasma membrane localisation of the p.Q597R protein was promoted with thapsigargin, an inducer of ER stress, whereas 4-PBA is known to alleviate ER stress (14) by acting as a chaperone itself (13) as well as inducing the expression of endogenous chaperone proteins (15) . The exact nature of the mutation could also be important. Indeed, our data does show that the specific location of the mutation is an important determinant of the capacity for functional rescue. For example, the p.Y1767D mutant showed a much enhanced by guest, on November 9, 2017 
